
## **Äke Svensson**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3746578/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 729-747.	2.4	329
2	Prevalence of contact allergy in the general population in different European regions. British Journal of Dermatology, 2016, 174, 319-329.	1.5	259
3	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2717-2744.	2.4	220
4	Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2016, 175, 69-79.	1.5	115
5	European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARSâ€Covâ€2) infection and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e241-e242.	2.4	99
6	Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). British Journal of Dermatology, 2018, 178, e332-e341.	1.5	96
7	Validity of Diagnostic Codes and Prevalence of Physician-Diagnosed Psoriasis and Psoriatic Arthritis in Southern Sweden – A Population-Based Register Study. PLoS ONE, 2014, 9, e98024.	2.5	94
8	European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1644-1659.	2.4	85
9	Prevalence of skin disease in a population-based sample of adults from five European countries. British Journal of Dermatology, 2018, 178, 1111-1118.	1.5	75
10	Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 146-163.	5.7	71
11	Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. British Journal of Dermatology, 2016, 174, 594-601.	1.5	65
12	Metal sensitivity: positive history but negative test indicates atopy. Contact Dermatitis, 1986, 14, 57-60.	1.4	63
13	Prevalence of fragrance contact allergy in the general population of five European countries: a cross-sectional study. British Journal of Dermatology, 2015, 173, 1411-1419.	1.5	62
14	Prevalence of Contact Allergy to p-Phenylenediamine in the European General Population. Journal of Investigative Dermatology, 2016, 136, 409-415.	0.7	62
15	Measuring the impact of dermatological conditions on family and caregivers: a review of dermatologyâ€specific instruments. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1429-1439.	2.4	61
16	Self-reported hand eczema: symptom-based reports do not increase the validity of diagnosis. British Journal of Dermatology, 2002, 147, 281-284.	1.5	56
17	Temporal trends of phthalate exposures during 2007–2010 in Swedish pregnant women. Journal of Exposure Science and Environmental Epidemiology, 2018, 28, 437-447.	3.9	53
18	Topical corticosteroid phobia in atopic dermatitis: International feasibility study of the <scp>TOPICOP</scp> score. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 1713-1719.	5.7	52

#	Article	IF	CITATIONS
19	Prevalence of contact allergy to metals in the European general population with a focus on nickel and piercings: The EDEN Fragrance Study. Contact Dermatitis, 2018, 79, 1-9.	1.4	52
20	A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis. Current Medical Research and Opinion, 2011, 27, 1395-1406.	1.9	51
21	Quality of life measurement in acne. Position Paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 194-208.	2.4	51
22	Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patientâ€Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1633-1643.	2.4	51
23	Self-Reported Skin Morbidity among Adults: Associations with Quality of Life and General Health in a Norwegian Survey. Journal of Investigative Dermatology Symposium Proceedings, 2004, 9, 120-125.	0.8	46
24	Itch and Mental Health in Dermatological Patients across Europe: A Cross-Sectional StudyÂin 13 Countries. Journal of Investigative Dermatology, 2020, 140, 568-573.	0.7	44
25	Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Nonâ€Melanoma Skin Cancer. Journal of the European Academy of Dermatology and Venereology. 2019. 33. 816-827.	2.4	43
26	Which acne treatment has the best influence on healthâ€related quality of life? Literature review by the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. Journal of the European Academy of Dermatology and Venereology and Venereology, 2018, 32, 1410-1419.	2.4	36
27	Eyelid dermatitis: the rÃ1e of atopy and contact allergy. Contact Dermatitis, 1986, 15, 178-182.	1.4	35
28	Dermatologists across Europe underestimate depression and anxiety: results from 3635 dermatological consultations. British Journal of Dermatology, 2018, 179, 464-470.	1.5	32
29	Recurrent eczema herpeticum – a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1074-1079.	2.4	32
30	Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVIDâ€19 pandemic. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1666-1671.	2.4	30
31	Design and Feasibility of an International Study Assessing the Prevalence of Contact Allergy to Fragrances in the General Population: The European Dermato-Epidemiology Network Fragrance Study. Dermatology, 2010, 221, 267-275.	2.1	29
32	Quimp (quality of life impairment): an addition to the quality of life lexicon. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e181-e182.	2.4	28
33	European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVIDâ€19 (SARSâ€CoVâ€2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e308-e311.	2.4	27
34	Prevalence of Self-reported Skin Complaints and Avoidance of Common Daily Life Consumer Products in Selected European Regions. JAMA Dermatology, 2014, 150, 154.	4.1	26
35	Subjective stress reactivity in psoriasis – a cross sectional study of associated psychological traits. BMC Dermatology, 2015, 15, 6.	2.1	25
36	Body dysmorphia in common skin diseases: results of an observational, crossâ€sectional multicentre study among dermatological outpatients in 17 European countries*. British Journal of Dermatology, 2022, 187, 115-125.	1.5	25

#	Article	IF	CITATIONS
37	Socioeconomic Status and the Prevalence of Skin and Atopic Diseases in Five European Countries. Acta Dermato-Venereologica, 2019, 99, 309-314.	1.3	24
38	Risk of severe allergic reactions to COVIDâ€19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e362-e365.	2.4	24
39	European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e839-e842.	2.4	22
40	Methods to improve quality of life, beyond medicines. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 318-328.	2.4	22
41	Atopic dermatitis, educational attainment and psychological functioning: a national cohort study. British Journal of Dermatology, 2019, 180, 559-564.	1.5	20
42	Prenatal phthalate exposure was associated with croup in Swedish infants. Acta Paediatrica, International Journal of Paediatrics, 2018, 107, 1011-1019.	1.5	18
43	Associations of self-reported atopic dermatitis with comorbid conditions in adults: a population-based cross-sectional study. BMC Dermatology, 2020, 20, 23.	2.1	18
44	Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1614-1621.	2.4	18
45	Quality of life measurement in occupational skin diseases. Position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Occupational Skin Disease. Journal of the European Academy of Dermatology and Venereology, 2020, 34. 1924-1931.	2.4	17
46	The Southern Sweden Adolescent Allergy-Cohort: Prevalence of allergic diseases and cross-sectional associations with individual and social factors. Journal of Asthma, 2019, 56, 227-235.	1.7	15
47	Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. Journal of Dermatological Treatment, 2021, 32, 164-173.	2.2	15
48	Cross-Cultural Validation of the QualityÂofÂLife in Hand Eczema Questionnaire (QOLHEQ). Journal of Investigative Dermatology, 2017, 137, 1454-1460.	0.7	14
49	The significance of batch and patch test method in establishing contact allergy to fragrance mix I—EDEN Fragrance Study Group. Contact Dermatitis, 2019, 81, 104-109.	1.4	14
50	TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. British Journal of Dermatology, 2020, 182, 1423-1429.	1.5	14
51	Rheumatoid arthritis, gold therapy, contact allergy and blood cytokines. BMC Dermatology, 2002, 2, 2.	2.1	13
52	Skin exposure to scented products used in daily life and fragrance contact allergy in the European general population ―The <scp>EDEN</scp> Fragrance Study. Contact Dermatitis, 2021, 84, 385-394.	1.4	13
53	Incremental Costs for Psoriasis and Psoriatic Arthritis in a Population-based Cohort in Southern Sweden: Is It All Psoriasis-attributable Morbidity?. Journal of Rheumatology, 2016, 43, 640-647.	2.0	11
54	Observational study on Swedish plaque psoriasis patients receiving narrowband-UVB treatment show decreased \$100A8/A9 protein and gene expression levels in lesional psoriasis skin but no effect on \$100A8/A9 protein levels in serum. PLoS ONE, 2019, 14, e0213344.	2.5	11

#	Article	IF	CITATIONS
55	The diagnosis you wish you had never operated on: Pyoderma gangrenosum misdiagnosed as necrotizing fasciitis—a case report. Monthly Notices of the Royal Astronomical Society: Letters, 2017, 88, 231-233.	3.3	10
56	lgE sensitization in a cohort of adolescents in southern Sweden and its relation to allergic symptoms. Clinical and Molecular Allergy, 2019, 17, 6.	1.8	10
57	Income disparities in healthcare use remain after controlling for healthcare need: evidence from Swedish register data on psoriasis and psoriatic arthritis. European Journal of Health Economics, 2018, 19, 447-462.	2.8	9
58	Validation of a questionnaire algorithm based on repeated open application testing with the constituents of fragrance mix I. British Journal of Dermatology, 2020, 182, 955-964.	1.5	9
59	Tocilizumabâ€induced sarcoidosisâ€like reaction in a patient with giant cell arteritis. Clinical implications of a paradoxical phenomenon. International Journal of Dermatology, 2020, 59, 888-889.	1.0	9
60	Hidradenitis Suppurativa in Sweden: A Registry-Based Cross-Sectional Study of 13,538 Patients. Dermatology, 2020, 236, 281-288.	2.1	9
61	Effects of intense pulsed light in microstomia in patients with systemic sclerosis: A pilot study. Journal of Cosmetic and Laser Therapy, 2017, 19, 143-148.	0.9	8
62	Asymmetric contributions of seed and pollen to gene dispersal in the marsh orchid Dactylorhiza umbrosa in Asia Minor. Molecular Ecology, 2021, 30, 1791-1805.	3.9	8
63	Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 2153-2165.	2.4	6
64	Colophony as a marker for fragrance allergy in the general European population. British Journal of Dermatology, 2016, 174, 695-696.	1.5	5
65	Intervention study to evaluate the importance of information given to patients with contact allergy: a randomized, investigatorâ€blinded clinical trial*. British Journal of Dermatology, 2021, 184, 43-49.	1.5	5
66	Penile intraepithelial neoplasia, penile cancer precursors and human papillomavirus prevalence in symptomatic preputium: a crossâ€sectional study of 351 circumcised men in Sweden. BJU International, 2021, 127, 428-434.	2.5	5
67	Oral provocation of patients allergic to sesquiterpene lactones with German chamomile tea to demonstrate possible systemic allergic dermatitis. Contact Dermatitis, 2020, 83, 8-18.	1.4	4
68	Fast and Standardized Skin Grafting of Leg Wounds With a New Technique: Report of 2 Cases and Review of Previous Methods. Eplasty, 2016, 16, e14.	0.4	4
69	Pseudoangiomatous Xanthelasmoid Mastocytosis – a new histopathological entity. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e261-e263.	2.4	3
70	Selection process of measures for core outcome set should utilize the highest methodology level and should be maximally free of bias. Comment on â€iDQoL, CDLQI and the 45â€item CADIS received a sufficient content validity rating during the HOME VII meeting in Japan: a group discussion study'. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e208-e209.	2.4	3
71	Dermatology textbooks in Scandinavia should prepare medical students for ethnic diversity. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e697-e698.	2.4	3
72	Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD). Journal of Dermatological Treatment, 2022, 33, 2565-2570.	2.2	3

#	Article	IF	CITATIONS
73	Migration dermatology: an issue to consider?. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e86-e87.	2.4	2
74	Validation of questionnaire algorithm based on repeated open application testing with the constituents of fragrance mix II: the EDEN Fragrance Study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1692-1701.	2.4	2
75	Methodological aspects of assessing hand eczema: comparison of two tools and three different categories of evaluators. British Journal of Dermatology, 2017, 176, 1373-1375.	1.5	1
76	Incidence of penile intraepithelial neoplasia and treatment strategies in Sweden 2000–2019. BJU International, 2022, , .	2.5	1
77	FS08.5†Does childhood atopic dermatitis influence the future working life?. Contact Dermatitis, 2008, 50, 153-154.	1.4	0
78	FS11.2†Contact allergy to herbal teas from Asteraceae plants. Contact Dermatitis, 2008, 50, 162-162.	1.4	0
79	P55†Nordic Occupational Skin Questionnaire (NOSQ-2002). Contact Dermatitis, 2008, 50, 198-199.	1.4	0
80	FRI0368â€Incremental Costs Per Patient for Psoriasis and Psoriatic Arthritis in a Population-Based Referent Cohort in Southern Sweden: Are there Clear Links to Psoriasis Morbidity?. Annals of the Rheumatic Diseases, 2015, 74, 559.2-560.	0.9	0
81	THU0636â€Assessment of Functional Status and Health-Related Quality of Life Instruments in A Population-Based Cohort of Patients with Psoriatic Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 424-425.	0.9	0
82	Building the evidence base for current systemic treatments for severe, chronic atopic dermatitis: methotrexate vs. azathioprine. British Journal of Dermatology, 2018, 178, 1236-1237.	1.5	0
83	Prevalence of contact allergies in the population compared to a tertiary referral patch test clinic in Jena/Germany. Contact Dermatitis, 2021, 85, 563-571.	1.4	0
84	Pharmacist recommendations regarding topical steroid use may contradict the standard of care in atopic dermatitis: An international, cross-sectional study. JAAD International, 2021, 4, 13-14.	2.2	0
85	Impact on quality of life of an intervention providing additional information to patients with allergic contact dermatitis; a randomized clinical trial. Journal of the European Academy of Dermatology and Venereology, 0, , .	2.4	0